Objectives: To explore the pharmacokinetics (PK) and pharmacodynamics (PD) of micafungin in patients undergoing continuous venovenous haemofiltration (CVVH).
Introduction
Among advances in antifungal drug development for invasive candidiasis, the echinocandin class represents the most recent addition, and has become first-line therapy. 1 Micafungin is an echinocandin, a lipopeptide that exhibits concentration-dependent fungicidal activity against most species of Candida 1 and is approved in Europe and the USA for the treatment of invasive candidiasis including candidemia. 2 The most frequent Candida sp. in candidaemia is Candida albicans (≈54%), followed by Candida parapsilosis (≈14%), Candida glabrata (≈14%) and Candida tropicalis (≈12%). 3 Micafungin exhibits high intrinsic activity against Candida spp. (MIC 90 ¼0.03 mg/L for C. albicans, MIC 90 ¼0.06 mg/L for C. glabrata and C. tropicalis, and MIC 90 ¼2 mg/L for C. parapsilosis). 3 Candidaemia is a nosocomial infection with high mortality (40% -60%). 4 In a prospective, multicentre observational study carried out in Spain, mortality was associated with age, Candida spp. different from C. parapsilosis and inadequate treatment. 5 Treatment adequacy is, therefore, the only measure for which an intervention could reduce mortality.
The risk for Candida infection of endogenous origin is increased in intensive care patients due to long-term and multiple antibiotic use, the use of steroids or other immunosuppressive drugs, the use of catheters and renal replacement therapy. 6 In critically ill patients, acute renal failure is a common complication, and renal replacement therapy is used for blood purification. It has been reported that this procedure can eliminate a significant amount of some drugs such as antifungals; 7 despite this, pharmacokinetic (PK) studies are rare in critically ill patients undergoing renal replacement therapy. Two small studies in Japan have suggested that micafungin concentrations are not affected by renal replacement therapy. 7, 8 The importance of reaching adequate micafungin concentrations is closely related to the adequacy of values for AUC 0 -24 /MIC, the pharmacodynamic (PD) parameter linked to the clinical efficacy of micafungin. 9 Using data from small studies, Monte Carlo simulations generate a large number of patient values according to an underlying statistical distribution, and estimate the probability of achieving a specific value for a PD index in a large population, with a target attainment rate that should be ≥90%.
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Clarification of the PK/PD relationship of micafungin in critically ill patients receiving renal replacement therapy would be useful to improve treatment adequacy. The aim of this study was to assess the influence of continuous venovenous haemofiltration (CVVH) on the PK of micafungin, and to explore its PK/PD adequacy, in the early phase of treatment for invasive candidiasis.
Patients and methods
A PK study was carried out in 10 critically ill adult patients admitted to the Anaesthesiology and Surgical Critical Care Department, Hospital La Paz, Madrid, Spain from April to December 2012. Patients were receiving CVVH and were treated with micafungin for invasive candidiasis. Patients were included in the study before or within 24 h of treatment initiation. The study protocol was approved by the ethics committee of Hospital La Paz, and written informed consent was obtained from patients (or relatives if the patient was not capable) before study inclusion.
Demographic data, disease severity (APACHE II), renal failure classification (RIFLE), 11 sequential organ failure assessment (SOFA) 12 and risk of invasive candidiasis (Candida score) 13 were calculated and recorded. CVVH was performed with the Aquarius System (Baxter, Berkshire, UK). A polyethersulphone haemofilter with a membrane surface of 1.2 m 2 (Aquamax HF 12, Bellco, Mirandola, Italy) was used in the first six patients and a polysulphone haemofilter with a membrane surface of 1.5 m 2 (Diacap Acute, B. Braun Melsungen AG, Melsungen, Germany) for the remaining four patients. The dialysis membranes were not changed during the sampling time. The standard blood flow rate was 160 -200 mL/min and was adjusted according to clinical demand. The ultrafiltration rate was 25 mL/min. Bicarbonate solution was infused as reposition fluid (50% pre-dilution and 50% post-dilution) at a rate that depended on balanced fluid therapy.
Once daily, patients were treated with 100 mg of micafungin (Astellas Pharma SA, Spain) diluted in 100 mL isotonic saline solution that was infused over 60 min by an infusion pump. Micafungin was infused into a venous catheter that was different from the venous catheter used for CVVH. Blood samples were drawn on Day 1 and Day 2 from the arterial prefilter port and venous post-filter port of the extracorporeal circuit at the start and end of infusion and at 3, 5, 8, 18 and 24 h. Ultrafiltration samples from the outlet of the ultrafiltrate compartment of the haemofilter were also taken at each sampling time. Urine samples were collected at 24 h when possible. Micafungin concentrations were determined using a validated HPLC method 14 Calibration of the chromatograph was accomplished using the external standard method, and linear calibration curves were calculated from the peak areas of micafungin compared with the external standard by spiking drug-free human serum and ultrafiltrate with standard solutions of micafungin. The assay was linear over the concentration range 0. 
PK analysis
The concentration -time data were analysed using non-linear mixedeffects modelling (NONMEM version 7.1, Globomax LLC, Hanover, USA). A digital Fortran compiler was used and the runs were executed using Wings for NONMEM. 15 The first-order conditional estimation method with interaction was used throughout the model building. Pre-filter plasma micafungin concentrations were fitted to one-, two-or three-compartment linear models using subroutines from the NONMEM library.
Between-subject variability (BSV) and between-occasion variability (BOV) were evaluated using an exponential variability model. Various models for residual unexplained variability (RUV) were also tested.
The elimination t1 2 was calculated from 0.693/k el . The area under the plasma drug concentration-time curve (AUC 0 -24 ) was calculated by the log-linear trapezoidal rule. Comparisons between pre-and post-filter concentrations and AUC 0 -24 values were performed using the Wilcoxon test. P, 0.01 was considered statistically significant.
Population PK model diagnostics
Visual inspection of diagnostic scatter plots and the NONMEM objective function value (OFV) were used to evaluate goodness of fit. Statistical comparison of nested models was undertaken in the NONMEM program using log-likelihood ratios, which are assumed to be x 2 distributed. On the basis of a x 2 test of the difference in OFV, a decrease in the OFV of 3.84 units (P,0.05) for one degree of freedom was considered statistically significant. A decrease of ≥10% in BSV of one of the parameters was also accepted for inclusion in a more complicated model.
Population PK covariate screening
Covariate model building was performed in a stepwise fashion with forward inclusion and backward deletion based upon the aforementioned model selection criteria. Age, sex, weight, serum bilirubin, creatinine, urea and albumin concentrations, as well as presence of vasopressor therapy, were evaluated as covariates.
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Population PK bootstrap
A non-parametric bootstrap method (n ¼ 1000) was used to study the uncertainty of the PK parameter estimates in the final model. From the bootstrap empirical posterior distribution, we were able to obtain the 95% CI (2.5% percentile to 97.5% percentile) for the parameters, as described previously. 16 
Generation of large population data
Four 9999-subject Monte Carlo simulations (Crystal Ball v.7.3.1, Decisioneering Inc., Denver, CO, USA) were performed using pre-filter and post-filter AUC 0 -24 /MIC ratios on Day 1 and Day 2 to evaluate the probability of achieving the target PK/PD values described for micafungin efficacy: 285 for C. parapsilosis, 3000 for Candida spp. (all species) and 5000 for non-parapsilosis Candida spp. 9 Log-normal distributions were assumed for AUC 0 -24 values according to probability distribution. In the case of MICs, fixed MIC values from the discrete distribution between 0.004 mg/L and 4 mg/L were considered. A probability of target attainment (PTA) ≥90% was considered optimal. Cumulative fraction responses (CFRs) were calculated using MIC distributions reported for C. albicans, C. glabrata and C. parapsilosis by EUCAST for calculation of epidemiological breakpoints. 17 Specifically, PTA values determined at each MIC were multiplied by the fraction of isolates found at that MIC, and the sum of the products equalled the CFR. A value ≥90% CFR against a population of organisms was considered optimal. Table 1 shows detailed demographic and clinical data including individual values of calculated indices. Median (range) age was 73.5 (54 -83) years; eight patients were male. The reason for intensive care unit (ICU) admission was severe sepsis in five cases and septic shock in one. Values for SOFA and Candida score in all but one patient were ≥8 and ≥4, respectively. Figure 1 shows mean micafungin concentrations (pre-and post-filter) at all sampling times on Days 1 and 2 [see also Table S1 (Day 1), Table S2 (Day 2) and Figure S1 , available as Supplementary data at JAC Online]. Mean micafungin concentrations in post-filter samples were higher than those in pre-filter samples at all sampling times except for trough samples, although differences were significant (P, 0.01) only at 3, 5, 18 and 24 h on Day 2. On Day 1, mean C max was 7.25+0.95 mg/L in samples from arterial pre-filter ports and 8.00+1.56 mg/L in those from venous post-filter ports (P ¼0.035), and mean trough concentration was 2.20+0.93 mg/L in samples from arterial pre-filter ports and 2.38+0.80 mg/L in those from venous post-filter ports (P ¼ 0.065). On Day 2, mean C max values were 9.15+1.95 mg/L (arterial pre-filter port) and 9.99+2.41 mg/L (venous post-filter port) (P ¼ 0.012), and mean trough concentrations were 2.46+0.75 mg/L (arterial pre-filter port) and 3.05+ 1.08 mg/L (venous post-filter ports) (P ¼ 0.005). Concentrations on Day 2 were higher than those on Day 1, but differences did not reach statistical significance.
Results
No differences were found between concentrations determined in patients using the polyethersulphone haemofilter and those using the polysulphone haemofilter. Concentrations in ultrafiltrate samples were below the quantification limit for all patients. Urine samples were available from six patients; concentrations were below the quantification limit (0.1 mg/L) for all patients except one (Patient 7; 0.15 mg/L). Table 2 Maseda et al.
using the polyethersulphone haemofilter and those using the polysulphone haemofilter.
Population PK analysis
The best base model for micafungin consisted of a twocompartment linear model with zero-order input with combined additive -exponential RUV. BSV was supported on CL as well as V of the central (Vc) and peripheral (Vp) compartments. BOV over two sampling occasions was also supported on CL as well as Vc and Vp. Body weight normalized to 70 kg (and an exponential of 0.75) applied to CL was the only covariate that statistically improved the model and was therefore included. Figure 2 displays the goodness-of-fit plots for micafungin. Of the samples included in the analysis, only four had a concentration greater than two standard deviations outside that predicted by the model, which we considered acceptable given the sickness severity and likely PK heterogeneity of the patient cohort. All other visual predictive checks were acceptable and confirmed the goodness of fit of the model. The plots in Figure 2 show that the final PK model adequately describes the measured concentrations.
The values of the parameters for the final models are given in Table 3 and include the 95% CIs for the parameters computed from all bootstrap runs. Table 4 details the individual PK parameters of the included patients. Table 5 shows PTA by MIC value. As shown in the table, no differences in MIC coverage (the highest MIC value with PTA ≥90%) were found pre-and post-filter: Day 1 (MIC ¼ 0.125 mg/L for the AUC 0 -24 /MIC cut-off of 285, MIC ¼ 0.016 mg/L for 3000 and MIC ¼ 0.008 for 5000); Day 2 (MIC ¼ 0.25 mg/L for the AUC 0 -24 / MIC cut-off of 285, MIC ¼ 0.016 mg/L for 3000 and 5000). PTA ≥90% at Day 2 was obtained for MICs equal to or only one dilution higher than at Day 1. Figure 3 shows PTA by MIC values for the three species in relation to MIC distribution. For C. albicans and C. glabrata, the MIC distribution was within the area covered by adequate PTAs, using AUC 0 -24 /MIC target values of both 3000 (all Candida spp.) and 5000 (non-parapsilosis Candida spp.), in contrast to the MIC distribution for C. parapsilosis, which was outside the area of adequate PTAs using AUC 0 -24 /MIC target values of both 285 (C. parapsilosis) and 3000. Related to this, Table 6 shows the CFRs determined for the each of three species. The global probability of achieving adequate values for AUC 0 -24 / MIC differed by species. For C. albicans, CFR was .90% on Day 2 using 3000 and 5000 as target values, showing more adequate values on Day 2 than on Day 1 using the 5000 cut-off value. For C. glabrata, CFR was .90% on Days 1 and 2 using 3000 as target value, but not using 5000, although the probability reached 89.46% with post-filter concentrations on Day 2. For C. parapsilosis, CFRs were , 10% regardless of study day, pre-or post-filter concentrations or target value (285 or 3000).
Discussion
Steady-state concentrations of antimicrobials are usually used for the calculation of PD parameters, yet PD adequacy in the early phase of treatment, when patients are often haemodynamically unstable, is crucial since the first 24 -48 h of treatment are of paramount importance in the outcome for critically ill patients. 18, 19 In the present study, the PK of micafungin in patients undergoing CVVH was assessed using two haemofilter membranes commonly used worldwide. The mean peak concentration found in our study after the first dose was higher than that reported in another single-dose study with the same micafungin dose in healthy volunteers, 20 but similar to that observed in stem cell transplant recipients 21 and in patients with haematological malignances. 22 Another study performed in a more similar population, liver transplant recipients undergoing CVVH, also observed a lower C max but a higher AUC compared with our results, despite the fact that these values were obtained after administering multiple doses of micafungin. 7 By contrast, a single-dose study performed in patients with severe renal dysfunction reported higher Micafungin PK/PD and CVVH in ICU patients 1627 JAC values for C max and AUC, but similar values for V and CL. 23 One important finding of our study is that micafungin was not removed by CVVH, because we observed higher concentrations and AUC 0 -24 values in samples collected from venous post-filter ports than pre-filter ports, regardless of the haemofilter membrane used. This may be due (in addition to plasma water removal during CVVH, resulting in an increased solute concentration) to a lack of adsorption of micafungin to the membranes used. In addition, no differences in the ratio of pre-and post-filter concentrations of micafungin were observed over time (during the first and second day of treatment), which suggests that the filter was not saturated.
Previous studies using different systems for renal replacement therapy have suggested that micafungin is not effectively removed from blood because of its high degree of protein binding, which does not permit passage through the filter pore. 7, 8 Other authors have studied the PK of other antifungals in patients undergoing CVVH. Similar to our results, the PK of caspofungin seemed not to be affected by different renal replacement therapies. 24 By contrast, one study that determined the PK of anidulafungin in 10 critically ill patients observed that this echinocandin was not filtered, but that CVVH resulted in a drug loss of 20% owing to adherence to synthetic surfaces. 25 In agreement with our findings, a study that investigated the PK of daptomycin during CVVH in nine critically ill patients also reported higher postfilter than pre-filter concentrations. 26 Published data and the results from the present study, showing a lack of influence for renal replacement therapies on the removal of micafungin, indicate that no dose adjustment is needed for micafungin in patients undergoing renal replacement therapy, although individual levels of plasma proteins could influence drug removal. 27 In the present study, levels of plasma proteins were below the lower limit of normal (6 -8 g/dL) for all patients except for Patient 1, but no relationship could be found between levels of plasma proteins and removal of micafungin since postfilter concentrations were higher than pre-filter concentrations for all study patients. However, one limitation of this study is that total micafungin concentrations (unbound plus bound) were measured and not the free or unbound fraction only.
From the perspective of in vitro activity, the MIC distribution of micafungin is relatively similar for most Candida spp. 3, 17 However, its in vitro potency is reduced for C. parapsilosis, as occurs with all echinocandins, since most isolates are 50-to 100-fold less susceptible than other Candida spp. 9 An AUC 0 -24 /MIC ratio of 3000 has been associated with positive therapeutic outcome in animal models of disseminated candidiasis caused by C. albicans, but not for C. parapsilosis, with an AUC 0 -24 /MIC value associated with Maseda et al.
efficacy 7-fold lower than that for C. albicans. 28 Cut-offs obtained in animal models have been extrapolated to humans 9 using data from clinical trials with micafungin in the treatment of invasive candidiasis/candidemia. 2, 27 Our results (on Day 2, both pre-and post-filter) in patients undergoing CVVH therapy receiving micafungin for invasive candidiasis were similar to those reported by Andes et al. 9 in patients not receiving CVVH therapy. In both cases, target values would be expected to be attained for organisms with micafungin MIC values ≤0.25 mg/L for the cutoff of 285 and ≤0.016 mg/L for cut-offs of 3000 and 5000. Micafungin PK/PD and CVVH in ICU patients 1629 
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Considering per-species MIC distributions, 17 ≥90% probability of achieving a target AUC 0 -24 /MIC ratio of 3000 would be obtained for patients infected by C. albicans and C. glabrata, but not for C. parapsilosis (even when using the AUC 0 -24 /MIC ratio of 285). But previous animal model and epidemiological data suggest that C. parapsilosis is a less fit or virulent species, 29, 30 and this is probably the reason for the similar successful treatment percentage obtained with micafungin and liposomal amphotericin B in clinical trials in the subset of patients infected by C. parapsilosis. Maseda et al.
The results of the present study carried out in the early phase of micafungin treatment for invasive candidiasis in patients receiving CVVH showed: (i) lack of removal of micafungin by the replacement therapy, with concentrations in post-filter samples significantly higher than those in pre-filter samples; (ii) no need for dose adjustment; (iii) target AUC 0 -24 /MIC ratios, both preand post-filter, attained for organisms with MIC values ≤0.25 mg/L for the cut-off of 285 and ≤0.016 mg/L for 3000 and 5000; (iv) optimal PK/PD coverage for non-parapsilosis Candida spp.; and (v) pre-and post-filter PD equivalence. Micafungin PK/PD and CVVH in ICU patients
